More than three decades ago, the U.S. Food and Drug Administration (FDA) approved Bacillus Calmette-Guérin (BCG) as the first ...

Abbisko Therapeutics (HKEX Code: 02256) announced that its self-developed, highly selective small molecule FGFR4 inhibitor, irpagratinib (ABSK011), has received approval of Breakthrough ...

Cambridge: AstraZeneca has announced that Imfinzi (durvalumab) has been recommended for approval in the European Union (EU) ...

A new pre-surgery treatment strategy for inherited breast cancer has achieved an astonishing 100% survival rate, thanks to a ...

The average annual national percentage change in mortality from hepatocellular carcinoma from 2005 to 2023 was higher for rural vs urban residents.

The Food and Drug Administration (FDA) has approved the combination of nivolumab (Opdivo ®) plus ipilimumab (Yervoy ® ), both from Bristol Myers Squibb Company, as an option for first-line therapy for ...

The US Food and Drug Administration (FDA) has granted regenerative medicine advanced therapy (RMAT) designation to AbelZeta ...

Liver cancer refers to the development of malignant cells in liver, which is a vital organ responsible for essential ...

Study leveraged Pattern Discovery Engine™ to construct highly accurate model to predict whether or not a given cell is ...

China NMPA grants breakthrough therapy designation to Abbisko Therapeutics’ irpagratinib to treat hepatocellular carcinoma: Shanghai Tuesday, May 27, 2025, 10:00 Hrs [IST] Abbis ...

The therapy claims to be the first therapeutic agent to utilise molecularly defined biomarkers for precision-targeted HCC ...

Abbisko Cayman Limited ( ($HK:2256) ) has provided an announcement. Abbisko Therapeutics has announced that its small molecule FGFR4 inhibitor, ...